

John F De Groot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7877133/publications.pdf>

Version: 2024-02-01

124
papers

7,630
citations

93792

39
h-index

64407

83
g-index

126
all docs

126
docs citations

126
times ranked

12963
citing authors

#	ARTICLE	IF	CITATIONS
1	Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2022, 24, 855-871.	0.6	38
2	Imaging Primer on Chimeric Antigen Receptor T-Cell Therapy for Radiologists. <i>Radiographics</i> , 2022, 42, 176-194.	1.4	11
3	Clinical and survival characteristics of primary and secondary gliosarcoma patients. <i>Clinical Neurology and Neurosurgery</i> , 2022, 214, 107146.	0.6	4
4	Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective Study. <i>Neurosurgery</i> , 2022, Publish Ahead of Print, .	0.6	0
5	A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. <i>CNS Oncology</i> , 2022, 11, CNS87.	1.2	15
6	Blood-brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors. <i>Journal of Neuro-Oncology</i> , 2021, 151, 65-73.	1.4	31
7	Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. <i>Neuro-Oncology</i> , 2021, 23, 284-294.	0.6	78
8	PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 920-931.	0.6	58
9	The promise of DNA damage response inhibitors for the treatment of glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab015.	0.4	16
10	Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab082.	0.4	2
11	A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 1337-1347.	0.6	50
12	Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience. <i>Neuro-Oncology</i> , 2021, 23, 1252-1260.	0.6	11
13	Phase II Trial of Proton Therapy vs. Photon IMRT for GBM: Secondary Analysis Comparison of Progression Free Survival between RANO vs. Clinical Assessment. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab073.	0.4	1
14	RARE-23. DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR: A CASE SERIES. <i>Neuro-Oncology</i> , 2021, 23, i45-i45.	0.6	0
15	OTME-23. Single-cell transcriptomic and epigenomic immune landscape of isocitrate dehydrogenase stratified human gliomas. <i>Neuro-Oncology Advances</i> , 2021, 3, ii18-ii18.	0.4	0
16	Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine. <i>Nature Communications</i> , 2021, 12, 4228.	5.8	21
17	Abstract LB125: Pharmacokinetics of paxalisib in phase 2 clinical study in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status. , 2021, , .		0
18	IDH mutation status and the development of venous thromboembolism in astrocytoma patients. <i>Journal of the Neurological Sciences</i> , 2021, 427, 117538.	0.3	4

#	ARTICLE	IF	CITATIONS
19	Intrinsic Interferon Signaling Regulates the Cell Death and Mesenchymal Phenotype of Glioblastoma Stem Cells. <i>Cancers</i> , 2021, 13, 5284.	1.7	14
20	A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa146.	0.4	10
21	Aggressiveness of care at end of life in patients with high-grade glioma. <i>Cancer Medicine</i> , 2021, 10, 8387-8394.	1.3	9
22	Immunotherapy for Neuro-oncology. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 233-258.	0.8	4
23	Immune biology of glioma associated macrophages and microglia: Functional and therapeutic implications. <i>Neuro-Oncology</i> , 2020, 22, 180-194.	0.6	95
24	Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. <i>Nature Medicine</i> , 2020, 26, 39-46.	15.2	236
25	Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. <i>Neuro-Oncology</i> , 2020, 22, 539-549.	0.6	98
26	A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). <i>Neuro-Oncology</i> , 2020, 22, 705-717.	0.6	47
27	Current Role of Radiation Therapy in the Management of Malignant Central Nervous System Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 13-28.	0.9	9
28	EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 1395-1407.	3.2	26
29	Pineal parenchymal tumor of intermediate differentiation: a single-institution experience. <i>Neuro-Oncology Practice</i> , 2020, 7, 613-619.	1.0	7
30	Long-term survival among 5-year survivors of adolescent and young adult cancer. <i>Cancer</i> , 2020, 126, 3708-3718.	2.0	33
31	Neurologic Toxicities of Cancer Immunotherapies: a Review. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 27.	2.0	17
32	Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment Resistance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1954.	1.8	56
33	Robust detection of oncometabolic aberrations by ^1H - ^{13}C heteronuclear single quantum correlation in intact biological specimens. <i>Communications Biology</i> , 2020, 3, 328.	2.0	3
34	Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2020, 74, 36-40.	0.8	6
35	Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 3565-3577.	3.2	30
36	Immunotherapy for Neuro-Oncology. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 183-203.	0.8	10

#	ARTICLE	IF	CITATIONS
37	Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 423-436.	5.7	218
38	The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 157-164.	0.6	2
39	Depletion of CLK2 sensitizes glioma stem-like cells to PI3K/mTOR and FGFR inhibitors. <i>American Journal of Cancer Research</i> , 2020, 10, 3765-3783.	1.4	2
40	Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1609-1624.	0.9	8
41	Treatment strategies for glioblastoma in older patients: age is just a number. <i>Journal of Neuro-Oncology</i> , 2019, 145, 357-364.	1.4	12
42	Are we AKT-uually getting closer to making targeted therapy successful in breast cancer brain metastases?. <i>Neuro-Oncology</i> , 2019, 21, 1344-1345.	0.6	1
43	Effect of health disparities on overall survival of patients with glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 365-374.	1.4	9
44	Prospective Clinical Sequencing of Adult Glioma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 991-1000.	1.9	15
45	Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. <i>European Journal of Cancer</i> , 2019, 112, 83-93.	1.3	15
46	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , 2019, 25, 477-486.	15.2	932
47	Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [18F]FAZA PET In Vivo. <i>Cells</i> , 2019, 8, 1487.	1.8	20
48	Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , 2019, 576, 112-120.	13.7	320
49	Disparities along the glioblastoma clinical trials landscape. <i>Neuro-Oncology</i> , 2019, 21, 285-286.	0.6	6
50	Phase 1 leadâ€”in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. <i>Cancer</i> , 2019, 125, 424-433.	2.0	46
51	Pre-surgical connectome features predict IDH status in diffuse gliomas. <i>Oncotarget</i> , 2019, 10, 6484-6493.	0.8	14
52	Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1411-1418.	0.6	24
53	Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome. <i>Journal of Neuro-Oncology</i> , 2018, 139, 125-133.	1.4	26
54	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1240-1250.	0.6	64

#	ARTICLE	IF	CITATIONS
55	Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. <i>Neuro-Oncology</i> , 2018, 20, 259-267.	0.6	41
56	Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. <i>Neuro-Oncology</i> , 2018, 20, 249-258.	0.6	78
57	Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 295-305.	3.2	68
58	Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. <i>Journal of Neurosurgery</i> , 2018, 129, 35-47.	0.9	178
59	Chimeric antigen receptor T-cell therapy " assessment and management of toxicities. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 47-62.	12.5	1,659
60	Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 113-122.	0.6	56
61	DDIS-03. EGFR AMPLIFICATION INDUCED INCREASED DNA DAMAGE RESPONSE AND PREDICTED SELECTIVE SENSITIVITY TO TALAZOPARIB (PARP INHIBITOR) IN GLIOBLASTOMA STEM-LIKE CELLS. <i>Neuro-Oncology</i> , 2018, 20, vi69-vi69.	0.6	0
62	INNV-13. ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi140-vi141.	0.6	0
63	PATH-08. THE IVY GLIOBLASTOMA PATIENT ATLAS - A NOVEL CLINICAL AND RADIO-GENOMICS RESOURCE FOR EARLY PHASE CLINICAL TRIAL DESIGN AND INTERPRETATION. <i>Neuro-Oncology</i> , 2018, 20, vi159-vi159.	0.6	0
64	ATIM-12. NEOADJUVANT ANTI-PD-1 IMMUNOTHERAPY PROMOTES INTRATUMORAL AND SYSTEMIC IMMUNE RESPONSES IN RECURRENT GLIOBLASTOMA: AN IVY CONSORTIUM TRIAL. <i>Neuro-Oncology</i> , 2018, 20, vi3-vi3.	0.6	1
65	NIMG-03. RADIOMIC TEXTURE ANALYSIS TO PREDICT RESPONSE TO IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, vi176-vi176.	0.6	1
66	ATIM-07. WINDOW-OF-OPPORTUNITY CLINICAL TRIAL OF PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi2-vi2.	0.6	0
67	ATIM-29. NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM). <i>Neuro-Oncology</i> , 2018, 20, vi7-vi7.	0.6	0
68	STEM-11. DIRECTED NEURONAL DIFFERENTIATION AS A THERAPEUTIC STRATEGY FOR MALIGNANT GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi246-vi246.	0.6	0
69	INNV-15. ANALYSIS OF CHALLENGES TO ACCRUAL IN CLINICAL TRIALS FOR NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi141-vi141.	0.6	0
70	ACTR-27. PHASE 2 STUDY OF DIANHYDROGALACTITOL (VAL-083) IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi17-vi17.	0.6	2
71	ATIM-10. A PHASE I/II CLINICAL TRIAL OF AUTOLOGOUS CMV-SPECIFIC CYTOTOXIC T CELLS (CMV-TC) FOR GLIOBLASTOMA: DOSE ESCALATION AND CORRELATIVE RESULTS. <i>Neuro-Oncology</i> , 2018, 20, vi2-vi3.	0.6	4
72	EPID-08. EFFECT OF HEALTH DISPARITIES ON OVERALL SURVIVAL OF PATIENTS WITH GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi81-vi81.	0.6	0

#	ARTICLE	IF	CITATIONS
73	ACTR-51. PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/MTOR INHIBITOR GDC-0084 GIVEN TO GLIOBLASTOMA (GBM) PATIENTS WITH UNMETHYLATED O6-METHYLGUANINE-METHYLTRANSFERASE PROMOTER STATUS. <i>Neuro-Oncology</i> , 2018, 20, vi23-vi23.	0.6	0
74	ACTR-34. INTEGRATED CLINICAL EXPERIENCE WITH ONC201 IN PREVIOUSLY-TREATED H3 K27M-MUTANT GLIOMA PATIENTS. <i>Neuro-Oncology</i> , 2018, 20, vi19-vi19.	0.6	3
75	RARE-13. CHARACTERIZATION OF ADULT MEDULLOBLASTOMA PATIENTS AT RECURRENCE: RETROSPECTIVE REVIEW OF THE MD ANDERSON CANCER CENTER EXPERIENCE. <i>Neuro-Oncology</i> , 2018, 20, vi239-vi239.	0.6	1
76	Lower-grade gliomas: the wrong target for bevacizumab. <i>Neuro-Oncology</i> , 2018, 20, 1559-1560.	0.6	2
77	EXTH-12. EFFECT OF THE PROTEIN ARGININE METHYLTRANSFERASE PRMT5 INHIBITION IN GLIOMA STEM-LIKE CELLS. <i>Neuro-Oncology</i> , 2018, 20, vi87-vi87.	0.6	0
78	IMMU-48. GLIOMA IMMUNE PROFILING REVEALS UNIQUE IMMUNE THERAPEUTIC OPPORTUNITIES. <i>Neuro-Oncology</i> , 2018, 20, vi132-vi132.	0.6	0
79	DRES-05. MOLECULAR EVOLUTION OF DIFFUSE GLIOMAS AND THE GLIOMA LONGITUDINAL ANALYSIS CONSORTIUM. <i>Neuro-Oncology</i> , 2018, 20, vi76-vi76.	0.6	0
80	The prognostic value of maximal surgical resection is attenuated in oligodendroglioma subgroups of adult diffuse glioma: a multicenter retrospective study. <i>Journal of Neuro-Oncology</i> , 2018, 140, 591-603.	1.4	38
81	A Coclinal Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models. <i>Clinical Cancer Research</i> , 2018, 24, 6288-6299.	3.2	74
82	Treatment of Glioblastoma in the Elderly. <i>Drugs and Aging</i> , 2018, 35, 707-718.	1.3	11
83	Highlighting the need for reliable clinical trials in glioblastoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1031-1040.	1.1	12
84	Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 437-442.	0.9	72
85	Ependymomas overexpress chemoresistance and DNA repair-related proteins. <i>Oncotarget</i> , 2018, 9, 7822-7831.	0.8	8
86	The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells. <i>Oncotarget</i> , 2018, 9, 10497-10509.	0.8	18
87	Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 132, 181-188.	1.4	16
88	Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. <i>Neuro-Oncology</i> , 2017, 19, 1047-1057.	0.6	325
89	CATNON interim results: another triumph of upfront chemotherapy in glioma. <i>Neuro-Oncology</i> , 2017, 19, 1287-1288.	0.6	1
90	Stabilization of phosphofructokinase 1 platelet isoform by AKT promotes tumorigenesis. <i>Nature Communications</i> , 2017, 8, 949.	5.8	191

#	ARTICLE	IF	CITATIONS
91	Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. <i>Clinical Cancer Research</i> , 2017, 23, 5745-5756.	3.2	53
92	CMET-09. PAN-CANCER PROFILES OF BRAIN METASTASES: PRIORITIZATION OF THERAPEUTIC TARGETS. <i>Neuro-Oncology</i> , 2017, 19, vi40-vi41.	0.6	0
93	NIMG-28. INCREASED MUTATION BURDEN (HYPERMUTATION) IN GLIOMAS IS ASSOCIATED WITH A UNIQUE RADIOMIC TEXTURE SIGNATURE IN MAGNETIC RESONANCE IMAGING. <i>Neuro-Oncology</i> , 2017, 19, vi147-vi148.	0.6	1
94	NIMG-01. DIFFUSION MRI PHENOTYPES PREDICT OVERALL SURVIVAL BENEFIT FROM ANTI-VEGF MONOTHERAPY IN GLIOBLASTOMA AT FIRST OR SECOND RELAPSE. <i>Neuro-Oncology</i> , 2017, 19, vi142-vi143.	0.6	0
95	DRES-09. THERAPEUTIC TARGETING OF CLK2 AND PI3K/mTOR IN GLIOBLASTOMA STEM CELLS. <i>Neuro-Oncology</i> , 2017, 19, vi65-vi65.	0.6	0
96	Targeting intercellular adhesion molecule-1 prolongs survival in mice bearing bevacizumab-resistant glioblastoma. <i>Oncotarget</i> , 2017, 8, 96970-96983.	0.8	24
97	A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma. <i>Oncotarget</i> , 2017, 8, 90488-90495.	0.8	13
98	Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma. <i>Oncotarget</i> , 2016, 7, 26793-26805.	0.8	37
99	Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. <i>Neuro-Oncology</i> , 2016, 18, 1357-1366.	0.6	116
100	Melanoma central nervous system metastases: current approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 627-642.	1.5	102
101	A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 129, 487-494.	1.4	52
102	Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 129, 147-154.	1.4	36
103	Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2187-2197.	1.9	69
104	Prioritization schema for immunotherapy clinical trials in glioblastoma. <i>Onc Immunology</i> , 2016, 5, e1145332.	2.1	13
105	Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models. <i>Neuro-Oncology</i> , 2016, 18, 1230-1241.	0.6	55
106	Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. <i>Neuro-Oncology</i> , 2016, 18, 557-564.	0.6	432
107	Adult brainstem gliomas: Correlation of clinical and molecular features. <i>Journal of the Neurological Sciences</i> , 2015, 353, 92-97.	0.3	44
108	Recurrent encephaloclastic cyst induced by intraventricular topotecan. <i>Journal of the Neurological Sciences</i> , 2015, 349, 52-53.	0.3	6

#	ARTICLE	IF	CITATIONS
109	Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 266-273.	0.6	61
110	Seek and Destroy: Relating Cancer Drivers to Therapies. <i>Cancer Cell</i> , 2015, 27, 319-321.	7.7	5
111	Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. <i>Journal of Neuro-Oncology</i> , 2015, 125, 401-410.	1.4	59
112	Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy. <i>Oncotarget</i> , 2015, 6, 31479-31492.	0.8	27
113	Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects. <i>Clinical Cancer Research</i> , 2014, 20, 5612-5619.	3.2	129
114	Pregnancy and glial brain tumors. <i>Neuro-Oncology</i> , 2014, 16, 1289-1294.	0.6	76
115	B lymphoblastic leukemia/lymphoma presenting as seventh cranial nerve palsy. <i>Neurology: Clinical Practice</i> , 2013, 3, 532-534.	0.8	0
116	Antiangiogenic Therapy for Glioblastoma: The Challenge of Translating Response Rate into Efficacy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e71-e78.	1.8	9
117	Antiangiogenic Therapy for Glioblastoma: The Challenge of Translating Response Rate into Efficacy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e71-e78.	1.8	5
118	Modulating Antiangiogenic Resistance by Inhibiting the Signal Transducer and Activator of Transcription 3 Pathway in Glioblastoma. <i>Oncotarget</i> , 2012, 3, 1036-1048.	0.8	71
119	Glutamate and the biology of gliomas. <i>Glia</i> , 2011, 59, 1181-1189.	2.5	246
120	Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept. <i>Clinical Cancer Research</i> , 2011, 17, 4872-4881.	3.2	59
121	High-Dose Antiangiogenic Therapy for Glioblastoma: Less May Be More?. <i>Clinical Cancer Research</i> , 2011, 17, 6109-6111.	3.2	17
122	Bevacizumab and Irinotecan in the Treatment of Recurrent Malignant Gliomas. <i>Cancer Journal (Sudbury, Mass)</i> , 2008, 14, 279-285.	1.0	57
123	New molecular targets in malignant gliomas. <i>Current Opinion in Neurology</i> , 2007, 20, 712-718.	1.8	32
124	The Excitatory Amino Acid Transporter-2 Induces Apoptosis and Decreases Glioma Growth In vitro and In vivo. <i>Cancer Research</i> , 2005, 65, 1934-1940.	0.4	80